By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Eli Lilly's (LLY) high valuation (26.3x forward P/E) is at risk due to intense competition in the GLP-1 market, manufacturing constraints, and uncertainty around AI-driven drug development. While Lilly has promising pipeline candidates, competitors like Amgen and Novo Nordisk could erode pricing power and market share before Lilly can scale production.
Risk: Manufacturing constraints leading to market share loss and margin pressure before Lilly can scale production.
Opportunity: Lilly's data on Mounjaro for MASH and heart failure creating a defensive moat in the GLP-1 ecosystem.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Even with growing competition in its core area, Eli Lilly could remain the leader.
The company is pursuing other opportunities that may boost its profits.
The drugmaker's medium-term outlook is bright, even at current levels.
It's been a volatile year for Eli Lilly (NYSE: LLY). The company's shares trended lower through the end of April, dropping well below $900. However, the drugmaker's first-quarter update, released on April 30, jolted the stock. Eli Lilly has been on a bit of a run over the past two weeks, with its shares climbing above $1,000, as of this writing. Could the pharmaceutical leader keep the momentum going and eventually reach $2,000 per share anytime soon?
Eli Lilly's work in diabetes and weight loss is doing most of the heavy lifting right now. The company's financial results have been outstanding thanks to its dominance in the anti-obesity market. But within the next few years, more weight management medicines will enter the market. Here are several that investors should watch out for. First, Novo Nordisk -- Eli Lilly's biggest rival -- has already requested approval for its next-gen therapy, CagriSema, which could launch by the end of the year, pending approval. Novo Nordisk is also running phase 3 studies for a candidate called Amycretin.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Amgen is another company working on a promising weight-loss medicine, MariTide, which is undergoing pivotal studies. MariTide has an advantage: It could be administered once a month, while Eli Lilly's Zepbound is taken weekly. There is Viking Therapeutics' VK-2375, another phase 3 asset, and Roche is advancing its own candidate, CT-388, into phase 3 studies. Even assuming a 50% success rate -- and considering this list is not exhaustive -- it's reasonable to predict that we could have a handful of additional weight-loss medicines on the market within the next five years.
That could pressure Eli Lilly and disrupt its pricing power. However, Eli Lilly has its own late-stage candidates, some of which have shown best-in-class potential. Retatrutide is the most notable. It delivered a 28.7% mean weight loss in a 68-week phase 3 study, which is much better than what Eli Lilly's current crown jewel and market leader, Zepbound, did in similar trials. Eli Lilly's pipeline also features mazdutide, a medicine already approved in China.
Even with more competition, Eli Lilly looks likely to stay ahead of the pack and remain the biggest winner in the fast-growing weight-loss market.
One key reason Eli Lilly could perform well even as new anti-obesity medicines challenge its own is that it isn't just a weight-loss stock. In the first quarter, the company posted strong sales growth from products in other fields, including oncology, immunology, and neuroscience.
Eli Lilly has doubled down on its efforts in these fields in recent years through strategic acquisitions that have expanded its pipeline. The company could make meaningful progress in these areas over the next few years that could jolt its stock price. There is another aspect of Eli Lilly's business worth considering: the company is exploring the use of artificial intelligence (AI) to improve the drug development process. The pharmaceutical giant built the industry's most powerful supercomputer with the assistance of Nvidia.
According to some research, AI could help cut the drug discovery process by one to two years. That may not sound like a lot, but this stage can account for up to 35% of drug development costs. Shortening it by a year while reducing the expenses pharmaceutical companies incur here could have a massive impact on a drugmaker like Eli Lilly, which has dozens of products in development. The company would bring drugs to market more cheaply and quickly, boosting profits and margins. It would also have more money to pour into R&D as a result.
It remains unclear whether Eli Lilly will achieve these goals in the next few years. But the company's AI-related work is worth monitoring closely, as it could unlock significant value for shareholders.
Eli Lilly is trading at 26.3x forward earnings, versus the average of 16.6x for the healthcare sector. Some might argue that Eli Lilly's success is already baked into the stock, leaving the company little room for error over the medium term. My view is that Eli Lilly is worth the premium. Although there will be clinical setbacks -- like with every drugmaker on planet earth -- the company is still well-positioned, given its deep pipeline in weight management and elsewhere, as well as its AI-related efforts. The stock could potentially double in the next six years, registering a compound annual growth rate of 12.25% over this period. That would require sustained execution, but Eli Lilly appears capable of achieving that level of growth.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $469,293! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,332!
Now, it’s worth noting Stock Advisor’s total average return is 993% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 18, 2026. *
Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, Nvidia, and Viking Therapeutics. The Motley Fool has positions in and recommends Amgen, Eli Lilly, and Nvidia. The Motley Fool recommends Novo Nordisk, Roche Holding AG, and Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Heightened competition in weight-loss therapies risks faster margin compression than the article's medium-term bullish case assumes."
Eli Lilly's GLP-1 leadership faces faster erosion than acknowledged, with Novo Nordisk's CagriSema launch targeted for late 2024 and Amgen's monthly MariTide entering phase 3. At 26.3x forward earnings versus the sector's 16.6x, any delay in Retatrutide or oncology uptake could trigger multiple compression. AI supercomputing with Nvidia may shave 1-2 years off discovery timelines, but this benefit accrues over a decade and does not offset near-term pricing pressure in a market that could see five additional approved therapies by 2029.
Retatrutide's 28.7% weight-loss data and mazdutide approval in China could still deliver outsized share gains that justify the premium multiple and push the stock toward $2000 within six years if execution stays flawless.
"LLY's $2,000 thesis requires three independent home runs (weight-loss pricing power, oncology/immunology breakthroughs, and AI cost reduction) when historically pharma stocks re-rate downward once one pillar weakens."
LLY at 26.3x forward P/E is pricing in flawless execution across three simultaneous bets: sustained weight-loss dominance despite a crowded pipeline, meaningful oncology/immunology growth, and AI-driven drug development ROI. The article treats these as independent upside levers, but they're correlated risks. Weight-loss margin compression (inevitable with competition) would force LLY to rely entirely on pipeline success in other fields—areas where it has no proven advantage over Amgen, Roche, or Novo Nordisk. The AI supercomputer claim is speculative; no pharma has yet proven 1-2 year discovery shortcuts translate to commercial value.
If retatrutide's 28.7% weight loss holds in real-world use and LLY maintains 60%+ market share through 2030, the company's EBITDA could grow 15%+ annually, justifying the premium multiple and a $2,000 target becomes rational.
"The current valuation of LLY leaves zero room for margin compression or clinical setbacks, making the path to $2,000 highly contingent on flawless execution in an increasingly crowded market."
Eli Lilly (LLY) is currently priced for perfection, trading at a steep forward P/E of ~26x compared to the broader healthcare sector's ~16x. While the GLP-1 market is massive, the article glosses over the 'margin compression' risk. As competitors like Amgen (MariTide) and Roche enter the fray, pricing power will inevitably erode. Furthermore, the reliance on AI for drug discovery is speculative; while it may shorten timelines, it doesn't guarantee clinical success or regulatory approval. Investors are paying a massive growth premium that assumes zero execution errors, yet the pharmaceutical space is historically prone to supply chain bottlenecks and unexpected safety signals that can crater valuations overnight.
If Retatrutide demonstrates superior efficacy and tolerability compared to all incoming competitors, LLY could maintain an effective monopoly on the premium weight-loss segment, justifying its current valuation multiple.
"Durable obesity drug momentum plus AI-enabled cost efficiencies are the linchpin for a multi-year re-rating of LLY to sustain 12%+ CAGR."
The article is broadly bullish on LLY, pegging upside to a durable obesity franchise, a broader non-obesity pipeline, and AI-driven drug development. It notes forward multiple still richer than peers (26.3x vs. 16.6x) and argues a six-year CAGR ~12% could lift shares to $2,000. Yet risks loom: Novo Nordisk and Amgen could erode pricing power with new entrants (CagriSema, Amycretin), payer pressure could compress margins, and AI payoff remains uncertain and costly. If obesity growth slows or regulatory deals tighten, the stock could re-rate lower despite pipeline upside. The carry is high; outcomes hinge on execution and timing of AI wins.
Against that, the article glosses over how quickly obesity competitors can win approvals and gain reimbursement; a few late-stage assets could crush pricing power, and AI-driven cost savings may take longer or be smaller than hoped.
"Capacity bottlenecks will compress margins before competition fully arrives."
Manufacturing shortages remain the clearest near-term constraint nobody has stressed. Lilly has already rationed Zepbound and Mounjaro launches; even if Retatrutide posts best-in-class data, volume cannot scale until new plants come online in 2026-27. That timeline collides directly with five expected competitor approvals, giving payers leverage to extract deeper rebates before Lilly can meet demand. The result is margin pressure arriving earlier than the 26x multiple implies.
"Manufacturing delays don't just compress margins—they cede market structure to faster competitors, making share recovery harder than the article implies."
Grok nails the manufacturing constraint, but undersells its severity. Lilly's 2026-27 capacity timeline means competitors launching in 2024-25 gain 18-24 months of unrationed market access and payer relationships. This isn't just margin pressure—it's market-share architecture. By the time Lilly scales, Amgen and Novo may own the formulary tier and patient loyalty. The 26.3x multiple assumes Lilly recaptures share through superior efficacy; it doesn't price in the friction cost of displacing entrenched competitors.
"Lilly’s valuation is anchored by secondary indication expansion, not just weight loss market share."
Claude, you’re missing the 'GLP-1 ecosystem' effect. This isn't just about weight loss; it’s about the massive, untapped cardiovascular and renal indications. Even if Amgen or Novo gain formulary access, Lilly’s data on Mounjaro for MASH and heart failure creates a defensive moat that pricing alone cannot breach. The real risk isn't just market share; it's the clinical trial failure rate in these secondary indications, which would collapse the current terminal value assumptions.
"AI ROI won't shield near-term margins; payer rebates and capacity-driven price discipline will drive margin compression into 2025-27."
Claude, your emphasis on AI-driven discovery ROI and correlated risk misses a key moat risk: payer-imposed rebates and formulary fragmentation will erode margins well before any AI shortcuts materialize into cash flow. Even if Mounjaro-like efficacy persists, Amgen and Novo Nordisk can win access with preferential pricing, and 2026-27 capacity constraints amplify price discipline. AI is a tailwind, not a near-term hedge against 2025-2027 margin compression.
Eli Lilly's (LLY) high valuation (26.3x forward P/E) is at risk due to intense competition in the GLP-1 market, manufacturing constraints, and uncertainty around AI-driven drug development. While Lilly has promising pipeline candidates, competitors like Amgen and Novo Nordisk could erode pricing power and market share before Lilly can scale production.
Lilly's data on Mounjaro for MASH and heart failure creating a defensive moat in the GLP-1 ecosystem.
Manufacturing constraints leading to market share loss and margin pressure before Lilly can scale production.